^
Association details:
| Biomarker: | FLT3-TKD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug Class: | FLT3 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
147 - Impact of FLT3 Inhibitor-Based Therapies on Outcomes of Acute Myeloid Leukemia (AML) Patients Receiving Allogenic Stem Cell Transplantation: A Retrospective Study
Published date:
12/16/2022
Excerpt:
All patients had an AML diagnosis with a FLT3 mutation…Of the 40 patients included in this study, 30 (75%) had the FLT3-ITD mutation, and 10 (25%) had the FLT3-TKD mutation….Post-HSCT maintenance, primarily with gilteritinib, resulted in improved OS and RFS in our patients. Amongst our patients receiving FLT3 inhibitors for maintenance, OS at 24 months was 96.2% and RFS was 89.7%.
